CereVasc raised $85 million in Series C funding to advance its minimally invasive eShunt system, which aims to treat ...
This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results